CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Antifungals, triazole derivatives
Updated · Methodology
Mechanism
Fluconazole moderately inhibits the enzyme CYP3A4 and prolongs the QT interval itself by directly inhibiting the potassium current IKr. Through CYP3A4 inhibition, it can also amplify QT prolongation caused by other drugs (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and fluconazole label, US Food and Drug Administration, FDA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and in vitro data suggest that drugs that markedly inhibit this enzyme may raise domperidone plasma levels (domperidone SmPC, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (AEMPS). The Spanish domperidone SmPC lists fluconazole among the contraindicated antifungals, but the documents do not say how much fluconazole raises domperidone levels (AEMPS). The half-life of fluconazole is about 30 hours, so its enzyme-inhibiting effect persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS, and FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Post-marketing reports of QT prolongation and torsade de pointes in people taking fluconazole are very rare, and these cases included seriously ill people with several risk factors, such as structural heart disease, electrolyte disturbances or concomitant medicines (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have also been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone SmPC, AEMPS). Low potassium and advanced heart failure raise the risk of life-threatening ventricular arrhythmias and torsade de pointes (fluconazole SmPC, AEMPS), and the risk of arrhythmia with domperidone also rises with high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names fluconazole among these antifungals (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish and US fluconazole documents contraindicate fluconazole with drugs that prolong the QT interval and are metabolised by the enzyme CYP3A4, and give pimozide, quinidine and erythromycin as examples (fluconazole SmPC, AEMPS, and fluconazole label, US Food and Drug Administration, FDA). Domperidone is not on that list, although according to its own SmPC it meets both criteria (domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Use fluconazole with caution in conditions that may cause arrhythmia (fluconazole SmPC, AEMPS). The enzyme-inhibiting effect of fluconazole persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS, and FDA label). No document gives a separate interval before starting domperidone. Use domperidone at the lowest effective dose, no more than 30 mg a day in adults, and usually for no longer than one week (domperidone SmPC, AEMPS). If domperidone and fluconazole have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Diflucan (fluconazole) prescribing information (2026)– FDA Diflucan label, DailyMed setid f694c617-3383-416c-91b6-b94fda371204, revised 04/2026, Contraindications and Drug Interactions
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fluconazol (Diflucan 100 mg) (nº registro 58804), sección 4.3 (2024)– AEMPS, CIMA, nº registro 58804 (Diflucan 50, 100, 150 y 200 mg cápsulas duras, Vinci Farma), revisión 07/2024 (texto revisado 02/2024), secciones 4.3 y 4.4